HKEX: 6628
Cancellation and grant of award pursuant to the share incentive scheme
View original source (HKEXnews)
Earlier from Transcenta
- Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
- Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
- Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
- Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics